Yes, Varivax is a live-attenuated vaccine. It contains a weakened form of the varicella-zoster virus, the same virus that causes chickenpox. The virus in the vaccine is alive but has been modified so it can trigger a strong immune response without causing full-blown disease.
What “Live-Attenuated” Means
Varivax uses a strain called Oka, named after a child in Japan from whom the original wild virus was isolated. Scientists weakened the virus through a process called serial passage, growing it repeatedly in lab cell cultures until it accumulated enough genetic changes to lose its ability to cause serious illness. Compared to the original wild virus, the vaccine strain carries about 42 genetic changes, 20 of which alter the proteins the virus produces. Several of these changes affect a key protein the virus needs to replicate aggressively, which is what keeps the vaccine strain tame.
Because the virus is still alive, it replicates just enough inside your body to teach your immune system what to look for. This tends to produce a broader, longer-lasting immune response than non-live vaccines. It’s also the reason Varivax comes with specific precautions that don’t apply to inactivated vaccines.
How Well It Works
A single dose of Varivax is 82% effective at preventing any form of chickenpox and nearly 100% effective at preventing severe cases. Two doses raise protection significantly: in clinical trials, two doses were 98% effective against any chickenpox and 100% effective against severe disease. Real-world studies after the vaccine hit the market show two doses are about 92% effective overall, with estimates ranging from 88% to 98%.
Children typically receive the first dose around 12 to 15 months of age and the second between 4 and 6 years old. Adults and older children who were never vaccinated or never had chickenpox also receive two doses, spaced at least 28 days apart.
Who Should Not Get Varivax
Because the vaccine contains a live virus, it’s not safe for everyone. People with severely weakened immune systems are at risk of the vaccine virus replicating beyond what their body can control. This includes people on high-dose immunosuppressive therapy, those with certain blood cancers, or anyone with a primary immune deficiency.
Varivax is also contraindicated during pregnancy. If you’re planning to become pregnant, the general guidance is to wait at least one month after vaccination. People with a known allergy to gelatin or the antibiotic neomycin, both of which are in the vaccine’s formulation, should not receive it either.
Common Side Effects
Side effects are generally mild and reflect the fact that a live virus is doing its job. In children 12 months through 12 years old, about 1 in 5 developed soreness, swelling, or redness at the injection site within three days of the first dose. That number rose slightly to about 1 in 4 after the second dose.
Fever occurred in about 7 out of 100 children after the first dose and 4 out of 100 after the second. Around 3 out of 100 children developed a mild chickenpox-like rash after the first dose, typically just a handful of spots near the injection site or scattered on the body. This rash dropped to about 1 in 100 after the second dose. These reactions are short-lived and far milder than an actual chickenpox infection.
Timing With Other Live Vaccines
The live-virus status of Varivax matters when scheduling other vaccinations. Varivax and the MMR vaccine (measles, mumps, rubella, another live vaccine) can be given on the same day with no issues. However, if they aren’t given on the same day, you need to wait at least four weeks between the two. Getting them too close together without that gap can reduce the immune response to the second vaccine, and the dose may not count.
This four-week spacing rule applies to all injectable and nasal-spray live vaccines. It does not apply to inactivated vaccines, which can be given at any interval before or after Varivax. Oral live vaccines like the rotavirus vaccine are also exempt from this rule and can be given on any schedule relative to Varivax.
Why Storage Matters for a Live Vaccine
Live vaccines are more fragile than inactivated ones because the virus needs to remain viable to work. Varivax must be stored in a refrigerator between 2°C and 8°C (about 36°F to 46°F), where it stays stable for up to 24 months. It can also be kept in a freezer, but once it’s been moved to a refrigerator, it cannot be refrozen. Exposure to temperatures outside this range can kill the weakened virus, rendering the vaccine ineffective. This is handled entirely by your provider’s office or pharmacy, but it’s the reason Varivax requires a cold chain from manufacturer to injection site.